sibeprenlimab

GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

Home
Ligands
sibeprenlimab

GtoPdb Ligand ID: 12102

Synonyms: sibeprenlimab-szsi | VIS-649 | VIS649 | Voyxact®

sibeprenlimab is an approved drug

Compound class: Antibody

Comment: Sibeprenlimab (VIS-649) is a fully humanized IgG2κ monoclonal antibody that targets the B-cell growth factor APRIL (TNFSF13) [2,5]. The antibody binds with high affinity to human trimeric APRIL, and potently blocks APRIL binding to its receptors TACI (transmembrane activator and CAML interactor) and BCMA (B-cell maturation antigen). APRIL mediates antibody class switching in mature B cells and promotes plasma-cell survival. APRIL acts to elevate production of IgA and pathogenic galactose-deficient IgA1, by mediating class switching in mature B cells and promoting plasma-cell survival. Galactose-deficient IgA1 is a key driver of the IgA nephropathy pathology. Hence targeting APRIL is considered as a mechanism to reduce IgA-mediated kidney damage.

Immunopharmacology Comments
APRIL is predicted to promote B cell class switching to IgA production via signalling through the Transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI). Elevated APRIL levels are associated with the pathology of IgA nephropathy. Hence, mAb-mediated neutralisation of APRIL to reduce TACI activation is a promising mechanism for the treament of IgA nephropathy.

Immunopharmacology Comments

APRIL is predicted to promote B cell class switching to IgA production via signalling through the Transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI). Elevated APRIL levels are associated with the pathology of IgA nephropathy. Hence, mAb-mediated neutralisation of APRIL to reduce TACI activation is a promising mechanism for the treament of IgA nephropathy.